Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera’s fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals.MET-233i was evaluate ...

文章核心观点 公司将在第85届美国糖尿病协会科学会议上展示其超长效、可扩展和可组合疗法组合的广度和进展，包括领先项目MET - 097i的最新临床和临床前研究结果 [1] 公司介绍 - 公司是一家临床阶段的生物制药公司，致力于加速开发治疗肥胖和代谢疾病的下一代药物 [10] - 公司正在推进一系列口服和注射用肠促胰岛素、非肠促胰岛素和联合疗法，以满足减肥治疗领域的未来需求 [10] - 公司成立于2022年，总部位于纽约市 [10] 展示内容 MET - 097i - 是公司完全偏向性、每月一次的超长效GLP - 1受体激动剂 [2] - 将展示两项临床数据，包括十二周每周给药和单次候选月剂量后的体重变化和耐受性数据 [2] MET - 233i - 是公司每月一次的超长效胰淀素类似物 [3] - 将展示临床前数据，包括详细的药代动力学和体重变化数据 [3] 展示详情 MET - 097i临床数据 - 《A Twelve - Week Trial of MET - 097—A Potent and Ultra - Long - Acting GLP - 1 Receptor Agonist》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）122号 [4] - 《Safety, Tolerability, PK, and Efficacy of MET - 097—A Next - Generation Nutrient - Stimulated Hormone Peptide Analog for Chronic Weight Management》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）088号 [4] MET - 097i临床前数据 - 《MET - 097: Preclinical Characterization of a Potent and Ultra - Long - Acting GLP - 1 Receptor Agonist》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）128号 [5] - 《Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET - 097, a G Protein - Biased GLP - 1R Agonist》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）133号 [6] MET - 233临床前数据 - 《MET - 233 Is an Ultra - Long - Acting Amylin Receptor Agonist》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）190号 [7] 管道项目临床前数据 - 《Therapeutic NuSH Cocktails—Coadministration of Ultra - Long - Acting GLP - 1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）100号 [8] 健康经济学和结果研究 - 《Titration to Maintenance Doses of GLP - 1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real - World Claims Dataset》，6月22日周日12:30 - 1:30pm CDT，海报厅（F1厅）093号 [9] 信息获取 - 可访问https://metsera.com/ada/了解公司在ADA会议的更多信息 [9] - 公司可能通过网站发布重要信息，可在investors.metsera.com获取 [11] - 可在投资者与媒体页面使用“电子邮件提醒”选项接收公司信息 [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Metsera, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 92-0931552 (State or other jurisdiction of incorporation or organization) 3 World Trade Center 175 Greenwich Street New York, New York 10007 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) For the quarterly perio ...

Exhibit 99.1 Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025 MET-097o, an oral formulation of MET-097i, has been accelerated and ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). A live webcast of the presentation will be available on the Events page in the Inv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-42489 Metsera, Inc. (Exact name of Registrant as specified in its Charter) Delaware 92-0931552 (State or other jurisdiction of incorp ...

Exhibit 99.1 Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o ...